论文部分内容阅读
氯氮平(C1ozapine)是一种有效的、很少导致锥体外系症状的抗精神病药物。由于1975年以来,发现该药可致粒细胞缺乏,因而对将其用来治疗精神分裂症有很大的争议。尽管该药目前已在22个国家正式出售,但在美国却一直是处于研究阶段,直至今年才获国家食品和药品管理局的批准。自1952年氯丙嗪问世以来,这些抗精神病药物对控制精神病急性阶段,以及延缓复发方面的效果已得到确认。但并不能以此认为这些药物的抗精神分裂症作用就十全十美,因为这些药物对有些精神分裂症病人疗效差或者根本无效,对精神分裂症的多种症状不能完全缓解或根本不能缓解,例如,对退
Clozapine is a potent antipsychotic that rarely causes extrapyramidal symptoms. Since 1975, the drug was found to cause agranulocytosis, and there is considerable controversy about its use to treat schizophrenia. Although the drug is currently on sale in 22 countries, it has been in the research phase in the United States until this year it was approved by the National Food and Drug Administration. Since the advent of chlorpromazine in 1952, the efficacy of these antipsychotics in controlling the acute phase of psychosis and in delaying relapse has been confirmed. However, the anti-schizophrenia effects of these drugs can not be considered as perfect because these drugs have poor efficacy or no effect on some schizophrenic patients and can not be completely relieved or not alleviated at all by various symptoms of schizophrenia. For example, Retreat